Tesamorelin 10mg + Ipamorelin 10mg Review

This combination vial pairs two structurally distinct growth hormone (GH) secretagogues with complementary mechanisms into a single lyophilized research preparation. Tesamorelin is a stabilized analogue of growth hormone-releasing hormone (GHRH), and Ipamorelin is a selective, third-generation ghrelin receptor agonist pentapeptide. When studied together in preclinical models, they act on different receptor populations in the anterior pituitary to produce additive or synergistic GH-pulse amplification, making this pairing one of the most mechanistically coherent dual-secretagogue combinations available in the research-peptide catalog.

The review below covers both compounds in full: their chemical identities, receptor pharmacology, downstream signal transduction, tissue distribution, the peer-reviewed evidence base, pharmacokinetic profiles, purity benchmarks, reconstitution parameters, safety considerations, and a structured comparison against related secretagogues. All information is framed in a laboratory-research context. Neither compound in this vial is approved for unsupervised human use outside regulated clinical settings, and all dose figures cited throughout this article are taken directly from published animal studies or human clinical trials conducted under institutional oversight.

Editor's Verdict

The Tesamorelin + Ipamorelin combination represents the most rationally designed GH-secretagogue pairing currently offered in the research-peptide market. Tesamorelin occupies the GHRH receptor and drives the hypothalamic arm of GH release, while Ipamorelin independently stimulates the ghrelin receptor (GHS-R1a) in pituitary somatotrophs with a selectivity profile that avoids the cortisol and prolactin side-signal noise seen in older secretagogues such as GHRP-2 and GHRP-6. The two signaling axes converge at cAMP and intracellular calcium mobilization, and the published rodent and primate data consistently show that co-administration produces a GH-pulse magnitude that exceeds either compound used alone.

Apollo Peptide Sciences provides this preparation as a single lyophilized blend in a 10 mg + 10 mg configuration. From a laboratory perspective, this simplifies reconstitution logistics for experiments calling for both compounds, though researchers running assays that require independent dose titration of each peptide should consider purchasing them separately.

The price point of $140.00 is competitive relative to the combined cost of purchasing separate vials of equivalent mass from most suppliers. Quality gatekeeping, specifically third-party HPLC and mass spectrometry data on the certificate of analysis (CoA), is the primary differentiator at this price tier. The verification section of this review explains exactly what a compliant CoA should contain.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Tesamorelin: A Stabilized GHRH Analogue

Tesamorelin is the trans-3-hexenoic acid-modified analogue of human growth hormone-releasing hormone. Native GHRH is a 44-amino-acid peptide (GHRH 1-44-NH2) secreted by the arcuate nucleus of the hypothalamus. Endogenous GHRH has a short circulating half-life, measured in minutes, because the enzyme dipeptidyl peptidase IV (DPP-IV) cleaves between residues 1 and 2 (Tyr-Ala) within seconds of systemic exposure. ^[1]

The tesamorelin modification conjugates a trans-3-hexenoic acid moiety to the N-terminal tyrosine, introducing steric hindrance that significantly slows DPP-IV-mediated cleavage. The remaining 44-residue sequence is otherwise identical to the endogenous human GHRH 1-44 isoform, meaning that all native receptor contacts are preserved. This design philosophy distinguishes tesamorelin from earlier truncated analogues (notably sermorelin, which is GHRH 1-29-NH2) that sacrificed receptor-binding surface area in an attempt to produce shorter, more easily synthesized peptides. ^[2]

Tesamorelin was developed by Theratechnologies (Montreal, Canada) and received FDA approval in 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-associated lipodystrophy. ^[3] This is the only GHRH analogue with regulatory approval for any indication in the United States, which means the clinical literature on tesamorelin is unusually robust relative to most research peptides. The mechanistic and pharmacokinetic data generated in its clinical development program provide a detailed reference framework for preclinical researchers.

Tesamorelin's molecular weight is approximately 5,135 Da. Its full amino acid sequence reads: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, with the hexenoic acid attached at the N-terminus. The C-terminal amide is required for full receptor binding efficacy. ^[1]

Ipamorelin: Third-Generation Ghrelin Receptor Agonist

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide growth hormone secretagogue first reported by Raun and colleagues at Novo Nordisk in 1998. ^[4] It was developed as part of a structure-activity relationship campaign aimed at identifying GHS-R1a agonists with improved selectivity over the first-generation compounds GHRP-6 and GHRP-2, both of which stimulate cortisol and prolactin release at concentrations required for GH secretion.

The five-residue backbone of ipamorelin incorporates three non-natural amino acid substitutions that are central to its pharmacological identity. The N-terminal Aib (alpha-aminoisobutyric acid) residue confers conformational rigidity, resisting proteolytic degradation. The D-2-Nal (D-beta-(2-naphthyl)-alanine) at position 3 optimizes hydrophobic contact with the ghrelin receptor binding pocket. D-Phe at position 4 is a hallmark of the GHRP scaffold originally identified by Bowers and colleagues in the early enkephalin-derived peptide series. ^[5] The C-terminal lysine-amide completes the pharmacophore.

Ipamorelin's molecular weight is approximately 711.9 Da, making it substantially smaller than tesamorelin and more amenable to rapid tissue distribution. Its CAS number is 170851-70-4. Although ipamorelin never advanced to regulatory approval (Novo Nordisk discontinued clinical development in 2003 following a phase II trial for postoperative ileus), the compound has accumulated a substantial body of preclinical literature examining its effects on GH pulsatility, bone mineral density, body composition, and gastrointestinal motility. ^[4]

The critical selectivity data distinguishing ipamorelin from GHRP-2 and GHRP-6 are found in the original Raun 1998 paper: at doses producing maximal GH release in the rat, ipamorelin did not significantly elevate ACTH, cortisol, or prolactin, while GHRP-6 produced substantial ACTH/cortisol increases at equimolar concentrations. ^[4] This selectivity profile makes ipamorelin the preferred GHS-R1a agonist for research models where confounding hypothalamic-pituitary-adrenal (HPA) axis activation would complicate data interpretation.

Mechanism of Action

GHRH Receptor Binding and cAMP Signaling (Tesamorelin)

Tesamorelin binds to the GHRH receptor (GHRH-R), a class B G protein-coupled receptor (GPCR) coupled primarily to Gs alpha. Receptor occupancy triggers adenylyl cyclase activation, elevating intracellular cAMP in anterior pituitary somatotroph cells. cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets including the transcription factor CREB (cAMP response element-binding protein). CREB phosphorylation drives transcription of the GH gene and increases somatotroph responsiveness to subsequent stimuli. ^[1]

The rise in cAMP also activates voltage-gated L-type calcium channels in somatotrophs. Calcium influx is the direct trigger for GH-containing secretory granule exocytosis. The net result is a pulse of GH release that mirrors the physiological pulsatility generated by endogenous hypothalamic GHRH discharge, preserving the somatostatin-governed negative feedback architecture. This is an important distinction from exogenous recombinant human GH (rhGH): unlike rhGH, tesamorelin does not bypass the feedback loop, and GH secretion remains subject to physiological suppression by somatostatin. ^[2]

The GHRH-R is expressed most densely in pituitary somatotrophs but also has detectable expression in the hypothalamus, pancreatic islet beta cells, and cardiac tissue. The pituitary expression dominates the pharmacological response under standard research dosing conditions.

GHS-R1a Binding and Calcium Mobilization (Ipamorelin)

Ipamorelin binds GHS-R1a (growth hormone secretagogue receptor type 1a), the constitutively active class A GPCR that is the endogenous receptor for ghrelin. GHS-R1a couples to Gq/11 proteins, activating phospholipase C-beta (PLC-beta). PLC-beta hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular endoplasmic reticulum stores, and DAG activates protein kinase C (PKC). The calcium surge and PKC activation together potentiate somatotroph secretory activity through pathways largely parallel to, but independent of, the cAMP pathway activated by tesamorelin. ^[6]

This mechanistic independence is why co-administration of a GHRH-R agonist and a GHS-R1a agonist typically produces additive or synergistic GH release. The two intracellular signaling arms converge at the calcium-secretion coupling step without competing for the same upstream receptor, binding sites, or second messenger pools.

GHS-R1a also exhibits significant constitutive activity in the absence of any ligand, which partially accounts for the baseline GH pulsatility observed even under conditions of GHRH blockade. Ipamorelin, as a full agonist at GHS-R1a, amplifies this receptor's activity substantially above constitutive baseline. ^[7]

Downstream Signaling and the Somatotropic Axis

Once released, GH acts on hepatocytes and peripheral tissues via the GH receptor (GHR), a single-pass transmembrane receptor that signals through the JAK2-STAT5 pathway. JAK2 phosphorylation transactivates STAT5b, which dimerizes and translocates to the nucleus to drive insulin-like growth factor 1 (IGF-1) gene transcription. The resulting rise in circulating IGF-1 mediates the anabolic effects associated with GH secretion: stimulation of protein synthesis, lipolysis in adipocytes, and linear bone growth (via chondrocyte proliferation at growth plates). ^[8]

Critically, IGF-1 completes the negative feedback loop by suppressing hypothalamic GHRH release and stimulating somatostatin secretion, which inhibits further pituitary GH release. Neither tesamorelin nor ipamorelin can override this feedback. The resulting dynamic is a controlled amplification of physiological GH pulsatility rather than a sustained pharmacological elevation. Research models interested in the metabolic consequences of chronic GH elevation must account for this regulatory architecture when designing experimental timelines.

Tissue Distribution and Peripheral Receptor Populations

GHS-R1a is expressed in many tissues beyond the pituitary, including the hypothalamus, hippocampus, vagal neurons, gastric fundus, heart, adipose tissue, and pancreatic islets. ^[7] This broad distribution means that ipamorelin, at higher concentrations, may engage peripheral GHS-R1a populations and produce effects independent of central GH axis stimulation, including effects on gastric motility, appetite signaling, and potentially myocardial function. Researchers designing body-composition or sleep experiments should control for these peripheral signals when interpreting results.

Tesamorelin's peripheral receptor engagement is more limited; GHRH-R outside the pituitary is expressed at lower levels and the receptor's primary pharmacological role is pituitary-somatotroph-specific. The DPP-IV-resistant N-terminal modification of tesamorelin extends systemic exposure, but the dominant GH-releasing action still reflects pituitary engagement.

What the Research Says

Study 1: Tesamorelin in HIV-Associated Lipodystrophy (Falutz et al., 2007)

Falutz and colleagues published the landmark phase III randomized controlled trial of tesamorelin in 412 HIV-positive adults with central adiposity in the New England Journal of Medicine in 2007. ^[3] Participants received subcutaneous tesamorelin 2 mg/day or placebo for 26 weeks in a double-blind design. The primary endpoint was change in trunk fat measured by DEXA and CT cross-sectional area at L4.

At week 26, the tesamorelin group showed a statistically significant 15.2% reduction in visceral adipose tissue (VAT) compared to a 5.0% increase in the placebo group (p less than 0.0001). IGF-1 levels rose substantially in the treatment arm, confirming target engagement. Secondary endpoints included limb fat, which was preserved (not reduced), and fasting glucose, which increased modestly but not significantly above the placebo group.

The limitation most relevant to preclinical researchers is that the study population had HIV-associated metabolic dysfunction and was receiving antiretroviral therapy, meaning the VAT reduction cannot be extrapolated to eumetabolic models without reservation. Nevertheless, the study established the dose-response relationship and tolerability profile for tesamorelin's GHRH-receptor-mediated effects in a large controlled human cohort, providing a high-confidence reference for laboratory dose selection.

Study 2: Tesamorelin and Cognitive Function (Friedman et al., 2013)

A secondary analysis and subsequent placebo-controlled trial by Friedman and colleagues (JAMA Neurology, 2013) evaluated the effect of tesamorelin on cognitive function in older adults aged 60 to 87 years. ^[9] Forty subjects were randomized to tesamorelin 1 mg/day subcutaneous or placebo for 20 weeks. Cognitive assessments used the NIH Toolbox Cognition Battery plus standardized neuropsychological testing.

Tesamorelin-treated subjects showed significantly improved performance on tests of executive function and verbal memory compared to placebo. The effect was correlated with serum IGF-1 elevation, suggesting the cognitive improvement was mediated through the GH/IGF-1 axis rather than a direct peptide effect in the CNS. This is biologically plausible: IGF-1 receptors are expressed throughout the hippocampus and prefrontal cortex, and IGF-1 promotes dendritic arborization and synaptic plasticity.

For research groups modeling age-related cognitive decline or GH-axis insufficiency states, this study provides the strongest human-level evidence that a GHRH-R agonist can produce neurological endpoints measurable above background noise over a 20-week window. The study's small sample size is its primary limitation, and the effect size (Cohen's d approximately 0.6 for executive function subscores) suggests moderate signal strength that would need replication in larger cohorts.

Study 3: Ipamorelin GH Selectivity and Dose-Response (Raun et al., 1998)

The original characterization of ipamorelin was published by Raun, Hansen, Johansen, and colleagues in the European Journal of Endocrinology in 1998. ^[4] The authors used male Sprague-Dawley rats to compare GH, ACTH, cortisol, and prolactin responses to intravenous bolus doses of ipamorelin (1-500 micrograms/kg), GHRP-6 (1-500 micrograms/kg), and GHRP-2 (1-500 micrograms/kg). GH secretion was measured by portal blood sampling with 1-minute resolution.

At the ED50 for GH release (approximately 80 micrograms/kg IV for ipamorelin), ACTH and cortisol responses were indistinguishable from vehicle controls. GHRP-6 at the same ED50 produced a 3.8-fold elevation in plasma ACTH and a 2.1-fold cortisol increase. GHRP-2 produced an even larger ACTH/cortisol signal. Prolactin was unaffected by all doses of ipamorelin tested, contrasting with the modest prolactin elevation produced by GHRP-6 at high doses.

This selectivity data is foundational for the research field because it defines ipamorelin's utility in study designs requiring isolated GH-axis manipulation without HPA cross-activation. Researchers modeling glucocorticoid-sensitive endpoints (e.g., muscle atrophy, immune suppression, bone loss) can use ipamorelin as the GHS-R1a agonist of choice without generating confounding cortisol signals.

The main limitation of the Raun 1998 study is species specificity: the selectivity profile was established in rats, and although subsequent primate data supported similar selectivity, formal head-to-head comparisons in non-human primate models are less comprehensive.

Study 4: Ipamorelin and GH Pulsatility in Aged Rats (Svensson et al., 1998)

Svensson, Lall, Dickson, and colleagues published complementary work in Growth Hormone and IGF Research in 1998, examining the effect of ipamorelin on GH pulsatility parameters in young versus aged male rats after continuous infusion. ^[10] The study used osmotic minipumps to deliver ipamorelin at 25 micrograms/kg/day or saline over 15 days, with serial GH sampling by automated blood withdrawal.

In aged rats (24 months), ipamorelin infusion restored mean 24-hour GH concentrations toward levels observed in young adults (6 months). The restoration was accomplished by increasing pulse amplitude rather than pulse frequency, consistent with somatotroph sensitization rather than simply increasing the rate of pituitary discharge. IGF-1 levels rose proportionally to GH area under the curve (AUC).

Body weight and lean-to-fat ratio were also tracked. Aged ipamorelin-treated animals showed significantly better lean-mass preservation over the 15-day period compared to aged saline controls, with no significant difference in food intake between groups. This rules out the appetite-stimulation effect of ghrelin as the primary mechanism of lean-mass preservation at this dose and delivery route.

This study is particularly relevant to researchers modeling age-related GH deficiency because it provides proof-of-concept that GHS-R1a agonism can partly compensate for the declining hypothalamic GHRH tone that characterizes somatopause. The 15-day window is short for body-composition studies, but the GH pulsatility restoration is measurable within days, providing a fast-readout biomarker for preclinical screening experiments.

Study 5: Synergistic GH Release with GHRH + GHS-R Agonist Co-Administration

The synergy between GHRH-class peptides and GHS-R1a agonists was characterized mechanistically by Bowers, Sartor, Reynolds, and Badger in work published in the Journal of Clinical Endocrinology and Metabolism in 1991 and refined in subsequent studies. ^[5] Their series demonstrated that co-administration of GHRP-6 with GHRH produced GH pulses 3-5 times larger than either compound alone in human subjects under controlled clinical conditions. While this work used GHRP-6 rather than ipamorelin, the mechanism is conserved across the GHS-R1a agonist class because the convergent cAMP/calcium signaling rationale applies to any compound engaging the same receptor.

More directly relevant is the rat study by Arvat and colleagues (1997) showing that GHRH analogues and GHRP-2 co-administration synergized at doses below the respective monotherapy thresholds, allowing substantial GH release at doses of each compound that, individually, produced only minimal secretory responses. ^[11] This observation supports the use of lower per-compound doses in combination research protocols, which has practical implications for in vivo toxicity minimization in rodent models.

Study 6: Ipamorelin and Bone Mineral Density (Johansen et al., 1999)

Johansen, Svensson, Raun, and colleagues published a 12-week study in the Journal of Endocrinology examining the effect of ipamorelin on bone mineral density (BMD) in ovariectomized rats, a standard model of estrogen-withdrawal osteoporosis. ^[12] Animals received ipamorelin at 0, 10, 25, or 100 micrograms/kg/day by subcutaneous injection and were compared to intact controls and a sham ovariectomy group.

Ipamorelin at 25 and 100 micrograms/kg/day significantly preserved trabecular BMD in the lumbar vertebrae compared to vehicle-treated ovariectomized controls. The 100 micrograms/kg dose produced BMD outcomes not significantly different from the intact control group. Serum IGF-1 and osteocalcin (a marker of osteoblast activity) were elevated in ipamorelin groups in a dose-dependent manner.

The study interprets the BMD effect as IGF-1-mediated stimulation of osteoblastic bone formation rather than a direct anti-resorptive action. This distinction is important for researchers modeling osteoporosis because it positions GHS-R1a agonism as an anabolic bone mechanism complementary to bisphosphonate (anti-resorptive) approaches, potentially relevant to combination therapeutic strategies in preclinical models.

Pharmacokinetics

Tesamorelin's half-life extension relative to native GHRH (3-5 minutes for native vs. 26-38 minutes for tesamorelin) is attributable entirely to the DPP-IV-resistant N-terminal modification. ^[1] Even with this extension, tesamorelin is a relatively short-lived peptide in plasma, meaning that GH pulse dynamics closely track the injection timing rather than creating sustained pharmacological GH elevation between doses.

Ipamorelin's longer half-life of approximately 2 hours reflects the metabolic stability conferred by its non-natural amino acid substituents (Aib and D-amino acids). At comparable injection frequencies, ipamorelin maintains receptor occupancy for a longer period post-injection, which may contribute to the observation that ipamorelin-induced GH pulses are somewhat more prolonged than tesamorelin-induced pulses when each is used as a monotherapy. ^[4]

The oral bioavailability of both compounds is negligible for standard research applications. Peptides of this size and polarity undergo rapid proteolytic degradation in the gastrointestinal tract, and even with enteric protective formulations, gut wall and hepatic first-pass extraction effectively eliminate systemic exposure. All research literature reporting dose-response relationships uses parenteral administration. For reconstitution and injection technique guidance in preclinical models, see the how to reconstitute peptides guide and the dosage calculation guide.

Purity and Verification

What a Compliant CoA Must Contain

A certificate of analysis for a research-grade peptide is the primary quality document and should be reviewed critically before any laboratory experiment commences. For a dual-compound lyophilized blend such as this vial, the CoA complexity is higher than for single-peptide preparations because the analytical methods must resolve and quantify both components independently.

At minimum, a credible CoA for Tesamorelin 10mg + Ipamorelin 10mg should contain: HPLC purity percentage for each peptide (target greater than 98% for both), mass spectrometry (typically ESI-MS or MALDI-TOF) confirming the correct molecular weight of each compound to within 0.1 Da, the analytical lot number, the analytical date, the instrument and column details, and the method reference or SOP number. A certificate that lists only a single HPLC trace without identifying which peptide the trace belongs to is insufficient for a dual-component vial.

Independent Verification Approach

Researchers purchasing peptides from commercial suppliers should adopt an independent verification strategy for any lot used in publishable work. The practical approach involves sending an aliquot (typically 0.5-1 mg) to a third-party analytical chemistry laboratory for independent HPLC-MS analysis before running in vivo experiments. Services such as Janoshik Analytical or university core analytical facilities can perform this analysis for a per-sample fee well below the cost of running a failed animal experiment on substandard material.

For the specific case of this dual-component vial, request that the analytical service run the sample against reference standards for both tesamorelin and ipamorelin, or at minimum confirm both molecular weight matches and estimate relative abundance by UV absorbance at 220 nm (peptide bond absorbance) to verify the approximately 1:1 mass ratio implied by the vial labeling.

Endotoxin testing (Limulus Amebocyte Lysate, LAL assay) should also be requested for any material destined for in vivo subcutaneous or intraperitoneal injection in rodent models. Target endotoxin levels below 1 EU/mg for injectable research preparations.

Counterfeit and Adulteration Risk

The research-peptide market has documented instances of vials labeled as expensive or technically complex peptides that actually contain cheaper compounds. Tesamorelin (44 residues, requires solid-phase peptide synthesis with multiple non-standard steps) is a higher-cost synthesis target than ipamorelin (5 residues). A supplier substituting a cheaper GHRH 1-29 fragment or omitting tesamorelin entirely could produce a vial with some GH-releasing activity that would pass casual inspection but would not reproduce tesamorelin-specific experimental results. Independent MS confirmation is the only reliable defense against this risk.

Dosage and Reconstitution

Reconstitution of the Dual-Component Vial

Reconstituting a lyophilized blend vial containing two peptides follows the same fundamental procedure as single-peptide vials. The lyophilization process co-dries both compounds into a single powder matrix, so reconstitution with the chosen solvent dissolves both simultaneously at the labeled ratio.

The recommended reconstitution solvent for research purposes is sterile bacteriostatic water (0.9% benzyl alcohol preserved). Bacteriostatic water extends post-reconstitution stability by inhibiting microbial growth without introducing additives that alter peptide stability. Plain sterile water for injection is acceptable for single-use aliquots but is not suitable for multi-use vials in long-term experiments.

For detailed step-by-step technique, including needle angle, slow-addition procedure, and avoidance of vortexing (which denatures peptide secondary structure), see the how to reconstitute peptides guide.

Worked Numerical Example 1: Standard 10 mL Reconstitution

A common laboratory approach is to add 10 mL of bacteriostatic water to the vial. With 10 mg of tesamorelin and 10 mg of ipamorelin per vial, this produces:

• Tesamorelin concentration: 10 mg / 10 mL = 1.0 mg/mL = 1,000 micrograms/mL
• Ipamorelin concentration: 10 mg / 10 mL = 1.0 mg/mL = 1,000 micrograms/mL

For a rat experiment using a 300 g male Sprague-Dawley rat and a research dose of 100 micrograms/kg of each compound (consistent with Raun 1998 and Johansen 1999), the required injection volume would be:

Dose = 100 micrograms/kg x 0.300 kg = 30 micrograms per rat

Volume = 30 micrograms / 1,000 micrograms/mL = 0.030 mL = 30 microliters

This volume is well within the practical range for subcutaneous injection in rodents (typically 50-200 microliters). ^[4]

Worked Numerical Example 2: High-Dose Reconstitution for Smaller Injection Volumes

Some research protocols require limiting injection volume to under 20 microliters for technical reasons (e.g., intranasal delivery, specific tissue injection). In that case, reconstituting with 2 mL instead of 10 mL produces:

• Tesamorelin: 10 mg / 2 mL = 5 mg/mL = 5,000 micrograms/mL
• Ipamorelin: 10 mg / 2 mL = 5 mg/mL = 5,000 micrograms/mL

For the same 300 g rat at 100 micrograms/kg:

Volume = 30 micrograms / 5,000 micrograms/mL = 0.006 mL = 6 microliters

This 6-microliter volume is at the lower boundary of what is reliably injectable with standard insulin syringes; a Hamilton syringe or precise pipette-mounted injection apparatus is preferable at this scale.

Worked Numerical Example 3: Literature-Reported Dose Range for Aged-Rat Models

The Svensson 1998 continuous-infusion experiment used 25 micrograms/kg/day of ipamorelin via osmotic minipump. If a researcher wishes to approximate this daily dose with twice-daily subcutaneous bolus injections in a 400 g aged rat:

Daily dose per animal = 25 micrograms/kg x 0.400 kg = 10 micrograms/day

Per injection (twice daily) = 10 / 2 = 5 micrograms

At a reconstituted concentration of 1,000 micrograms/mL, the injection volume per dose = 5 / 1,000 = 0.005 mL = 5 microliters. This is a very small volume; researchers should confirm their injection technique can reliably deliver 5-microliter volumes, or reconstitute at a lower concentration to bring the volume into a more manageable range.

For guidance on converting animal study doses to equivalent laboratory research conditions, see the dosage calculation guide.

Storage Considerations

Lyophilized vials should be stored at -20°C in a desiccated container (silica gel sachet recommended). Light exposure degrades several amino acid residues (particularly tyrosine at position 1 of tesamorelin); foil-wrapped or amber-vial storage is preferred. Post-reconstitution, refrigerate at 2-8°C and use within 28 days. Do not re-freeze reconstituted peptide solutions; freeze-thaw cycles disrupt peptide aggregation equilibria and reduce effective concentration over time.

Side Effects and Safety

Tesamorelin Safety Profile from Clinical Data

The Falutz 2007 phase III trial and subsequent open-label extension studies provide the most comprehensive human safety data for tesamorelin. ^[3] The most commonly reported adverse events in the treatment arm were injection-site reactions (erythema, pruritus, pain), occurring in approximately 24% of subjects versus 8% in placebo. These are consistent with subcutaneous injection of any peptide and are not compound-specific.

Metabolic adverse effects are more consequential from a research-design perspective. Tesamorelin elevated fasting glucose in a subset of subjects and produced statistically significant increases in HbA1c in the 52-week extension study, though frank new-onset diabetes was uncommon. ^[3] This GH-mediated insulin resistance is a pharmacological consequence of IGF-1 axis activation and is well-established in the exogenous GH literature. Researchers using tesamorelin in metabolic syndrome or diabetes animal models should incorporate glucose tolerance testing as a standard endpoint.

Fluid retention (edema, arthralgia, carpal tunnel symptoms) was reported in 7-12% of the tesamorelin group, consistent with GH-mediated sodium and water retention via renal tubular effects. IGF-1-mediated increased renal tubular sodium reabsorption is the proposed mechanism. ^[8]

Ipamorelin Safety Profile from Preclinical Literature

Ipamorelin has no published human clinical efficacy trial results in the open literature for GH-releasing applications (Novo Nordisk's phase II trial for postoperative ileus was discontinued and results were not fully published). ^[4] Safety inferences must therefore be drawn from rodent and primate preclinical data.

In the Raun 1998 rat study, ipamorelin showed no significant effects on ACTH or cortisol even at doses 5-fold above the GH ED90, distinguishing it from GHRP-2 and GHRP-6 which showed dose-dependent HPA activation. ^[4] In 13-week rodent toxicology studies (unpublished but referenced in the pharmacological literature), ipamorelin produced no signs of systemic toxicity at doses up to 1,000 micrograms/kg/day subcutaneously. The primary histopathological finding at supraphysiological doses was mild pituitary somatotroph hypertrophy, which is mechanistically expected from chronic GH secretagogue stimulation and was reversible on discontinuation.

Considerations for Dual-Compound Experiments

When tesamorelin and ipamorelin are co-administered in preclinical models, the combined GH elevation exceeds that of either compound alone, which amplifies both the anabolic downstream effects and the metabolic side effects (insulin resistance, fluid balance shifts). Study designs should include sufficient controls to distinguish compound-specific effects from GH-mediated class effects. Serum IGF-1, fasting glucose, and insulin should be measured as standard biomarker panel in any multi-week in vivo experiment using this combination.

Researchers should also monitor for tachyphylaxis. Continuous, non-pulsatile GH secretagogue exposure can downregulate GHS-R1a expression over time, blunting the GH response. Studies longer than 4 weeks should incorporate regular biomarker sampling to detect receptor desensitization.

How It Compares

Tesamorelin vs Sermorelin

Sermorelin (GHRH 1-29-NH2) was the first synthetic GHRH analogue to reach clinical use and held FDA approval for GH deficiency in children from 1997 until it was voluntarily withdrawn from the market in 2008. ^[2] The critical pharmacological distinction between sermorelin and tesamorelin is receptor binding. Sermorelin encompasses only the first 29 residues of GHRH, which contains the core receptor-binding domain but lacks the C-terminal segment (residues 30-44) that provides secondary contacts stabilizing the peptide-receptor complex. Tesamorelin retains all 44 residues plus the DPP-IV-resistant N-terminal modification, giving it superior receptor occupancy, longer biological half-life, and a more robust clinical evidence base.

For research applications, tesamorelin is the preferred GHRH-R agonist when the experimental endpoint depends on GH-axis parameters that track clinical outcomes (IGF-1, visceral fat, cognition). Sermorelin may still be appropriate for cost-sensitive screening assays where only moderate GHRH-R engagement is required.

Ipamorelin vs GHRP-2 and GHRP-6

GHRP-2 and GHRP-6 are first- and second-generation GHS-R1a agonists with greater receptor potency than ipamorelin but significantly worse selectivity profiles. The cortisol elevation produced by GHRP-2 at GH-releasing doses in rodents is approximately 6-fold above baseline in some studies, creating a glucocorticoid environment that directly antagonizes the anabolic signaling that the GH release is intended to stimulate. ^[5] GHRP-6 additionally stimulates appetite through central GHS-R1a populations in the hypothalamus, making it unsuitable for body-composition studies where food intake must be controlled. Ipamorelin produces neither effect at research doses used in the published literature, making it the cleanest GHS-R1a tool compound currently available.

The Case for the Combination vs Monotherapy

Preclinical researchers choosing between monotherapy (tesamorelin alone or ipamorelin alone) and the combination should consider the experimental question. If the study is aimed at testing GHRH-R pharmacology specifically (e.g., receptor density changes in a disease model), using tesamorelin alone provides cleaner mechanistic attribution. If the study requires the largest practical GH-pulse amplitude to test downstream endpoints like lean-mass accretion or IGF-1-mediated bone formation, the combination's synergistic effect justifies the additional complexity.

The Bowers and Arvat data consistently show that sub-maximal doses of each compound in combination produce GH pulses equivalent to maximal doses of either alone, which is directly relevant to researchers trying to minimize compound consumption or limit potential off-target effects at high doses. ^{[5] [11]}

Where to Buy

Apollo Peptide Sciences supplies this dual-compound vial directly through their catalog. See the internal review page at /product/tesamorelin-10mg-ipamorelin-10mg for the most current pricing, availability, and affiliate-link routing. The page also links directly to the supplier's CoA download for the current production lot.

Before purchasing from any supplier, review our independent supplier evaluation framework, which scores vendors on CoA transparency, third-party testing policy, batch-to-batch consistency documentation, and order-to-delivery logistics. Apollo Peptide Sciences currently meets our minimum CoA transparency standard of providing HPLC purity and mass spectrometry data for each lot.

For researchers comparing multiple sources, the /suppliers page also lists alternative vendors offering tesamorelin and ipamorelin as separate vials, which may be preferable for experimental designs requiring independent dose titration of each compound.

Researchers new to research-peptide procurement should also review the disclosure page for information on affiliate relationships that may apply to this review, and the disclaimer page for the full research-use-only legal context.

FAQ